Norbert Kraut: Co-targeting of KRASG12C plus SOS1 for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors
Norbert Kraut,Global Head of Cancer Research at Boehringer Ingelheim, shared on X:
“Out now in Nature Cancer Our brand-new paper shows co-targeting of KRASG12C plus SOS1 as strategy for treating KRAS-G12C inhibitor-naïve and relapsed mutant tumors. Thanks to MD Anderson Cancer Center, Tim Heffernan and team and congrats to the Boehringer Ingelheim KRAS team.”
Authors: Venu Thatikonda, Hengyu Lyu, Sabine Jurado, Kaja Kostyrko, Christopher A. Bristow, Christoph Albrecht, Donat Alpar, Heribert Arnhof, Oliver Bergner, Karin Bosch, Ningping Feng, Sisi Gao, Daniel Gerlach, Michael Gmachl, Melanie Hinkel, Simone Lieb, Astrid Jeschko, Annette A. Machado, Thomas Madensky, Ethan D. Marszalek, Mikhila Mahendra, Gabriella Melo-Zainzinger, Jessica M. Molkentine, Philipp A. Jaeger, David H. Peng, Robyn L. Schenk, Alexey Sorokin, Sandra Strauss, Francesca Trapani, Scott Kopetz, Christopher P. Vellano, Mark Petronczki, Norbert Kraut, Timothy P. Heffernan, Joseph R. Marszalek, Mark Pearson, Irene C. Waizenegger and Marco H. Hofmann.
Source: Norbert Kraut/X